Αποτελέσματα Αναζήτησης
2 ημέρες πριν · NCS Pearson. (2019). 4. Sparrow S, et. Al. Vineland Adaptive Behavior Scales-Third Edition (Vineland-3). ... Key exploratory measures include change in measures of clinical function: communication ...
2 ημέρες πριν · NCS Pearson. (2019). 4. Sparrow S, et. Al. Vineland Adaptive Behavior Scales-Third Edition (Vineland-3). NCS Pearson. (2016). 5. Improvement on ORCA exceeding proposed minimal clinically meaningful difference of ≥2. 6. Zigler CK, et al. Am J Intellect Dev Disabil. (2023). 7. Duke University.
2 ημέρες πριν · 1. Medium and high dose groups at 6 months. 2. Improvement exceeds Natural History. 3. Bayley N. Aylward GP. Bayley Scales of Infant and Toddler Development-Fourth Edition. NCS Pearson. (2019). 4. Sparrow S, et. Al. Vineland Adaptive Behavior Scales-Third Edition (Vineland-3). NCS Pearson. (2016). 5.
2 ημέρες πριν · 1. Medium and high dose groups at 6 months. 2. Improvement exceeds Natural History. 3. Bayley N. Aylward GP. Bayley Scales of Infant and Toddler Development-Fourth Edition . NCS Pearson. (2019). 4. Sparrow S, et. Al. Vineland Adaptive Behavior Scales-Third Edition (Vineland-3). NCS Pearson. (2016). 5.
2 ημέρες πριν · 1. Medium and high dose groups at 6 months. 2. Improvement exceeds Natural History. 3. Bayley N. Aylward GP. Bayley Scales of Infant and Toddler Development-Fourth Edition.NCS Pearson. (2019). 4.
2 ημέρες πριν · Ionis Pharmaceuticals (Nasdaq: IONS) announced positive results from the Phase 1/2 HALOS study of ION582 in people with Angelman syndrome (AS).The study showed consistent clinical improvement in communication, cognition, and motor function.Key findings include: - 97% of patients in medium and high dose groups showed improvement in overall AS symptoms
2 ημέρες πριν · ION582 showed robust and consistent benefit in communication, cognition and motor function in a broad patient population evaluated with a comprehensive set of assessment tools that collect input from...
